Try our Advanced Search for more refined results
Life Sciences
-
February 09, 2026
Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1
Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.
-
February 09, 2026
High Court Asked To Take Up Malpractice Case Against Akin
A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.
-
February 09, 2026
Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy
Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.
-
February 06, 2026
Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit
Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.
-
February 06, 2026
Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case
A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.
-
February 06, 2026
HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight
U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.
-
February 06, 2026
NJ Judge Tosses Pacira Investor Suit Over Patent Loss
A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.
-
February 06, 2026
Arizona Abortion Restrictions Found Unconstitutional
An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.
-
February 06, 2026
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test
The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.
-
February 06, 2026
3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study
Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court.
-
February 06, 2026
TPG Hid Exactech Defects To Dodge Liability, Trust Alleges
The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.
-
February 06, 2026
SEC Alleges Pharma Co. Misled Investors About Cancer Drug
The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.
-
February 06, 2026
Beasley Allen Disqualified From NJ Talc Multicounty Litigation
A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.
-
February 06, 2026
Insulet Gets $14.9M Fee Award For Trade Secret Trial Win
A Massachusetts federal judge awarded Insulet Corp.'s attorneys almost $15 million for their $452 million jury trial victory in a trade secrets dispute that was later reduced to $59.4 million, but the fees Goodwin Procter LLP netted were significantly less than the nearly $25 million it requested.
-
February 06, 2026
FLSA Does Not Bar Claim Waivers, Wash. Judge Says
The Fair Labor Standards Act does not categorically bar a contract's release of an employee's claims, a Washington federal judge ruled, finding that a former pharmaceutical manufacturing company worker's severance agreement that included a general release of claims precludes his wage suit.
-
February 06, 2026
HHS Ends 340B Drug Rebate Pilot After Legal Challenge
The U.S. Department of Health and Human Services has ended a proposed rebate program that would have altered how hospitals receive payments for participating in the federal 340B drug discount program, which provides discounted prescription drugs for low-income Americans, after facing a lawsuit from a major hospital association.
-
February 05, 2026
NYAG's Insider Trading Case A Power Grab, Judge Told
The former CEO of healthcare contractor Emergent BioSolutions Inc. has removed to federal court New York Attorney General Letitia James' insider trading case against him, alleging James is trying to expand her office's power through claims that concern questions of federal law.
-
February 05, 2026
Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax
The full Federal Circuit won't rethink a panel's refusal to revive claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy that a lower court found were invalid.
-
February 05, 2026
Judge Affirms Health Cos.' Sanctions For Witness Omission
An Illinois federal judge rejected a "vague and unsupported" bid by a home healthcare company accused of violating federal kickback laws to reconsider sanctions she ordered for failing to disclose witnesses, saying the motion "wastes everyone's time" and scolding the defendants for "impugning the character and professionalism of an able magistrate judge."
-
February 05, 2026
David Protein Gets Ingredient Supply Antitrust Claims Tossed
A New York federal court dismissed a lawsuit from several low-calorie food producers accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after it purchased the ingredient's only supplier.
-
February 05, 2026
Patent Co., AI Research Firm Join Forces In $150M Deal
Patent monetization venture SIM IP has announced a merger valued at $150 million with artificial intelligence research firm Garden Intel, a deal the companies said would create a first-of-its-kind platform.
-
February 05, 2026
Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'
Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day.
-
February 05, 2026
Medtronic Hit With $382M Antitrust Verdict Over Bundling
A California federal jury on Thursday ordered Medtronic to pay nearly $382 million to business rival Applied Medical for antitrust violations, finding the medical device giant illegally used its monopoly power to crush competition in the market for a type of surgical instrument called an advanced bipolar device.
-
February 05, 2026
Yale Health System Seeks $4.1M Coverage For Transplant
A Liberty Mutual unit breached a stop-loss insurance policy by denying Yale University's health system $4.1 million in coverage for a plan member's bone marrow transplant, the system told a Connecticut federal court.
-
February 05, 2026
Trump Admin Finalizes Rule Facilitating Federal Worker Firings
The Trump administration Thursday announced a final rule to create a new category of federal workers who would have fewer job protections and be easier to fire, implementing an executive order from early last year that could affect 50,000 employees at federal agencies.
Expert Analysis
-
4 Developments That Defined The 2025 Ethics Landscape
The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.
-
Navigating AI In The Legal Industry
As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.
-
How Fractional GCs Can Manage Risks Of Engagement
As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.
-
2025 Legal Milestones That Will Shape Psychedelics Sector
As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.
-
Series
Nature Photography Makes Me A Better Lawyer
Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.
-
What Defense Teams Must Know About PFAS Testing Methods
Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.
-
Series
Law School's Missed Lessons: Practical Problem Solving
Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.
-
Intellectual Property Challenges In AI-Driven Drug Discovery
Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.
-
Reel Justice: 'The Mastermind' And Juror Decision-Making
The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.
-
Learning From 2025 FCA Trends Targeting PE In Healthcare
False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.
-
Software Patents May Face New Eligibility Scrutiny
November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.
-
Opinion
A Uniform Federal Rule Would Curb Gen AI Missteps In Court
To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.
-
Riding The Changing Winds For AI Innovations At The USPTO
As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.
-
Series
The Law Firm Merger Diaries: Integrating Practice Groups
Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.
-
Opinion
Supreme Court Term Limits Would Carry Hidden Risk
While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.